SAN DIEGO, Feb. 8, 2012 /PRNewswire/ -- CareFusion, a
leading, global medical technology company, and Fisher & Paykel
Healthcare, a leading designer, manufacturer and marketer of
products and systems for use in respiratory care, acute care and
the treatment of obstructive sleep apnea, today announced a
three-year renewal of their longstanding agreement providing
CareFusion the exclusive right to distribute Fisher & Paykel
Healthcare products into the U.S. hospital market.
"For more than 25 years, we have partnered with Fisher &
Paykel Healthcare to bring its portfolio of clinically
differentiated respiratory solutions to U.S. hospitals," said
Vivek Jain, president of the
Procedural Solutions segment for CareFusion. "As we extend and
strengthen our strategic relationships with proven partners like
Fisher & Paykel Healthcare, our customers benefit from
continued access to market-leading technologies that help improve
the cost, quality and safety of patient care."
Under the agreement, CareFusion, through its AirLife™
Respiratory Consumables business, will continue to serve as the
exclusive U.S. distributor of Fisher & Paykel Healthcare's
extensive portfolio of respiratory consumable products, including
the MR850 Heated Humidification System with Evaqua™ circuit
technology, AIRVO™ high flow device, Optiflow™ nasal cannula, and
FlexiFit™ non-invasive interfaces.
"Through our extended partnership, Fisher & Paykel
Healthcare can leverage CareFusion's experience and expertise in
the respiratory and acute care markets to continue to grow our
business in the United States,"
said Justin Callahan, president of
U.S. operations for Fisher & Paykel Healthcare. "We have been
pleased with the strong relationships CareFusion's AirLife
team has established with U.S. hospitals and look forward to
continuing our longstanding partnership with CareFusion."
About CareFusion Corporation
CareFusion (NYSE: CFN) is a global corporation serving the
health care industry with products and services that help hospitals
measurably improve the safety and quality of care. The company
develops market-leading technologies including Alaris® infusion
pumps, Pyxis® automated dispensing and patient identification
systems, AVEA®, AirLife™ and LTV® series ventilation and
respiratory products, ChloraPrep® products, MedMined® services for
data mining surveillance, Nicolet™ neurological monitoring and
diagnostic products, V. Mueller® surgical instruments, and an
extensive line of products that support interventional medicine.
CareFusion employs more than 14,000 people across its global
operations. More information may be found at
www.carefusion.com.
About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare (NZSX: FPH, ASX: FPH) is a
leading designer, manufacturer and marketer of products and systems
for use in respiratory care, acute care and the treatment of
obstructive sleep apnea. The company's products are sold in
more than 120 countries worldwide. For more information about
the company, visit www.fphcare.com.
Cautions Concerning Forward-looking Statements
This news release and the information contained herein contains
forward-looking statements addressing expectations, prospects,
estimates and other matters that are dependent upon future events
or developments. The matters discussed in these forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially from those projected,
anticipated or implied. Forward-looking statements include, but are
not limited to, statements about the expected benefits of the
distribution agreement between CareFusion and Fisher & Paykel
Healthcare, as well as future growth opportunities that may result
from this and other relationships between the companies. The
forward-looking statements contained herein are based on current
expectations and assumptions and not on historical facts, and
actual results may differ materially if CareFusion and Fisher &
Paykel Healthcare fail to achieve the intended benefits of the
agreement. Additional factors that may affect CareFusion's
future results are described in its Form 10-K, Form 10-Q and Form
8-K reports (including all amendments to those reports) and
exhibits to those reports that CareFusion files with the U.S.
Securities and Exchange Commission. Except to the limited extent
required by applicable law, CareFusion undertakes no obligation to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
(Logo:
http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO)
SOURCE CareFusion
